Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.
about
Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adultsLow molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancerUnfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patientsLow molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancerAnticoagulation for patients with cancer and central venous cathetersAnticoagulation for patients with cancer and central venous cathetersVenous thromboembolic diseaseDirect-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryMeta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgeryPharmacology of anticoagulants used in the treatment of venous thromboembolismGuidance for the treatment of deep vein thrombosis and pulmonary embolismEnoxaparin in acute coronary syndromesEndothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopeniaThe management of heparin-induced thrombocytopenia.Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia.Testing for heparin-induced thrombocytopenia: are we there yet?Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes.Latest medical treatment strategies for venous thromboembolism.Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?Current concepts review: heparin-induced thrombocytopenia.Optimization of a murine immunization model for study of PF4/heparin antibodies.Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies.Low-molecular-weight heparin-induced skin necrosis: about 2 cases.Lepirudin in the management of patients with heparin-induced thrombocytopenia.Thrombocytopenia following percutaneous coronary intervention.Heparin-induced thrombocytopenia associated with pulmonary embolism.Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage.Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis.Fondaparinux: does it cause HIT? Can it treat HIT?IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics.Heparin-induced thrombocytopenia: present and future.Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literatureAnticoagulant utilization evaluation in a teaching hospital: a prospective study.Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients.Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry.Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approachHeparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin.
P2860
Q24193149-F0A9BFF0-7C50-4E5A-B42D-183FBF59A727Q24193749-D2B7F3C6-B3D5-4048-A0C6-1487BFC586F9Q24200589-9D54B74C-E62A-49BC-ACC0-4F8C57AF6004Q24235023-DC1BD8C6-DB94-4589-978C-84A32DE44D6CQ24235260-C660415C-F283-4C00-B3D4-19A4189818AFQ24236648-9489F753-289A-434D-B683-E7FFC5AE6A1BQ24631121-FAE26B3C-2401-4B3C-BE5C-8B9B7A00AD75Q26746917-8B8A9F4D-D431-4B86-8891-ECB2C5F7DEEBQ26828439-6DF22309-4B94-4F99-8E7F-4D49528CCFBDQ28072799-35BC46C7-1D6A-4BFC-8A5E-00CC104379EBQ28078967-5469BD4F-0B6A-479D-9306-DB2AA274783EQ28078989-A6254634-691F-41DE-BA9D-9F0A7BA6C352Q28301431-9CB83112-A703-4F9E-80DE-7D833979FFC2Q30840169-2B530139-2040-4A8D-875F-BCF23E846E0AQ33371013-3BBCA90F-AE62-4C48-97F9-9EA7C45E7A6DQ33374563-292158A3-E88C-4E4E-A6B9-DE0426B362C9Q33374916-F7505F14-32AB-4F3D-A8BA-270336935831Q33375177-4EFFC08A-DDA1-4E26-9A2F-8DE43C39C5CFQ33375535-EA9A3902-BAE2-4A86-8606-CF75CBE4776AQ33376013-F48BD442-D7F2-4503-BDD0-3E53B5055E03Q33382108-9BBCB6DE-79B5-4544-87CB-3009C9FB7EC7Q33383456-A7C46C71-88E5-46FF-A81D-C307DC0D1370Q33384840-EBA1019A-C464-4D28-98FA-9EDDBE976F70Q33385745-3DC3A478-F6AD-4054-A197-BD305DBD2ABEQ33385972-AC8F4806-AE4F-41BE-8A51-C82632728A83Q33387648-D5255B65-4FF4-47D3-BCE2-0596C85C8B55Q33387663-922A04B6-F9E8-4FBE-9CAA-9D988C567B7CQ33387713-C5FB4ED1-604F-49EA-9AC2-E4580B064825Q33391391-FDE45857-10E7-42C8-8177-3AEC9E611F35Q33392773-878CD41A-1B7A-41EA-8124-9DDB0053252FQ33392854-4B6CD762-4F46-4DBB-AA02-D6C19F7DA2F6Q33392864-E665639B-16AA-47F7-B182-78717CC9AADEQ33393788-13D0139A-3193-4411-81B4-2FCD5AABE066Q33394188-F561E782-2566-431A-806A-859652D249CBQ33394695-D12732EF-3C13-4796-8FA9-E3489261B117Q33394991-285EEDD1-A7F4-4D9E-A82E-C7125D155AD6Q33395517-C6FEAF9F-7981-4F09-972C-A46F64412967Q33395797-EDF59F5D-D39C-43A8-9453-344E79F176C4Q33396243-EB7CB470-BA67-4A24-A204-C6F63721806FQ33397666-FF9C4EBC-E3CE-44C3-A1C5-39A4E380A55D
P2860
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Risk for heparin-induced throm ...... oprophylaxis: a meta-analysis.
@ast
Risk for heparin-induced throm ...... oprophylaxis: a meta-analysis.
@en
type
label
Risk for heparin-induced throm ...... oprophylaxis: a meta-analysis.
@ast
Risk for heparin-induced throm ...... oprophylaxis: a meta-analysis.
@en
prefLabel
Risk for heparin-induced throm ...... oprophylaxis: a meta-analysis.
@ast
Risk for heparin-induced throm ...... oprophylaxis: a meta-analysis.
@en
P2093
P1433
P1476
Risk for heparin-induced throm ...... oprophylaxis: a meta-analysis.
@en
P2093
Nadine Martel
Philip S Wells
P304
P356
10.1182/BLOOD-2005-04-1546
P407
P577
2005-06-28T00:00:00Z